Fig. 2: Urotensin II-saporin treatment affects the breathing pattern and induces hypoxemia during sleep. | Nature Communications

Fig. 2: Urotensin II-saporin treatment affects the breathing pattern and induces hypoxemia during sleep.

From: Cholinergic basal forebrain degeneration due to sleep-disordered breathing exacerbates pathology in a mouse model of Alzheimer’s disease

Fig. 2

Stylized breathing traces based on the average measures of the polysomnography features recorded by whole body plethysmography and coincident EEG recordings in mice injected with control Blank-SAP (A, C) or UII-SAP (B, D) during wake (A, B) or sleep (C, D). Statistics refer to sleep-wake paired two-way ANOVA and Levene tests of variance of both male and female mice. E Average polysomnography measures for individual male mice in UII-SAP or control Blank-SAP groups (sleep-wake paired two-way ANOVA; mean ± s.d) f frequency, PIF peak inspiration flow, PEF the peak exhalation flow, EIP time for inspiration, EEP time for exhalation, RT: F Average blood oxygen saturation level of unrestrained UII-SAP- and Blank-SAP-injected male mice measured during their sleep period (P < 0.0001, Student’s unpaired two-tailed t-test; mean ± s.e.m). G Representative traces of blood oxygen saturation levels of male mice injected with either UII-SAP or control Blank-SAP. *P < 0.05, **P < 0.01, ***P < 0.001 ****P < 0.0001 n.s: non-significant. Each data point represents an individual animal.

Back to article page